One pill for obesity is already on the market, and more are on the way. But the injected drugs have key advantages.

Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.

Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping up to rival new oral treatments from Novo Nordisk A/S and Eli Lilly & Co.

March 16 (Reuters) - Structure Therapeutics' oral obesity drug aleniglipron delivered up to 16.3% weight loss when compared with a placebo after 44 weeks of treatment in a mid‑stage study, it said on ...

In this week’s STATus Report, host Alex Hogan explains why weight loss pills were so much harder to develop than injectables.

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.

As part of an investigation that dates back to 2023, the FDA has identified over two dozen products featuring the plant.

If you have obesity and are curious whether a weight loss medication could help you improve your health, there are a number of weight loss pills on the market to consider, both old and new.

The study also raised concerns about the risks of prolonged use of diet pills. Read more at straitstimes.com. Read more at ...